Catalyst Biosciences Inc. (CBIO)
Catalyst Biosciences Statistics
Share Statistics
Catalyst Biosciences has 37.98M shares outstanding. The number of shares has increased by 0% in one year.
| Shares Outstanding | 37.98M |
| Shares Change (YoY) | 0% |
| Shares Change (QoQ) | 0% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 1.83M |
| Failed to Deliver (FTD) Shares | 141.19K |
| FTD / Avg. Volume | 32.29% |
Short Selling Information
| Short Interest | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Valuation Ratios
The PE ratio is -2.02 and the forward PE ratio is null. Catalyst Biosciences's PEG ratio is 0.02.
| PE Ratio | -2.02 |
| Forward PE | n/a |
| PS Ratio | 20.96 |
| Forward PS | null |
| PB Ratio | -0.77 |
| P/FCF Ratio | -0.5 |
| PEG Ratio | 0.02 |
Enterprise Valuation
Catalyst Biosciences has an Enterprise Value (EV) of -4.99M.
| EV / Sales | -6.28 |
| EV / EBITDA | 0.1 |
| EV / EBIT | 0.15 |
| EV / FCF | 0.15 |
Financial Position
The company has a current ratio of 1.68, with a Debt / Equity ratio of 0.
| Current Ratio | 1.68 |
| Quick Ratio | 1.68 |
| Debt / Equity | 0 |
| Debt / EBITDA | 0 |
| Debt / FCF | 0 |
| Interest Coverage | -12.01 |
Financial Efficiency
Return on Equity is 38% and Return on Invested Capital is 41.53%.
| Return on Equity | 38% |
| Return on Assets | -28.98% |
| Return on Invested Capital | 41.53% |
| Revenue Per Employee | $113.43K |
| Profits Per Employee | $-1.18M |
| Employee Count | 7 |
| Asset Turnover | 0.03 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | 348K |
| Effective Tax Rate | -4.41% |
Stock Price Statistics
The stock price has increased by -0.25% in the last 52 weeks. The beta is 1.29, so Catalyst Biosciences's price volatility has been higher than the market average.
| Beta | 1.29 |
| 52-Week Price Change | -0.25% |
| 50-Day Moving Average | 0.5 |
| 200-Day Moving Average | 0.33 |
| Relative Strength Index (RSI) | 55.25 |
| Average Volume (20 Days) | 437.27K |
Income Statement
In the last 12 months, Catalyst Biosciences had revenue of 794K and earned -8.24M in profits. Earnings per share was -0.26.
| Revenue | 794K |
| Gross Profit | -4K |
| Operating Income | -8.61M |
| Net Income | -8.24M |
| EBITDA | -52.15M |
| EBIT | -7.18M |
| Earnings Per Share (EPS) | -0.26 |
Balance Sheet
The company has 21.67M in cash and 38K in debt, giving a net cash position of 21.63M.
| Cash & Cash Equivalents | 21.67M |
| Total Debt | 38K |
| Net Cash | 21.63M |
| Retained Earnings | -410.94M |
| Total Assets | - |
| Working Capital | - |
Cash Flow
In the last 12 months, operating cash flow was -33.1M and capital expenditures 0, giving a free cash flow of -33.1M.
| Operating Cash Flow | -33.1M |
| Capital Expenditures | 0 |
| Free Cash Flow | -33.1M |
| FCF Per Share | -1.05 |
Margins
Gross margin is -0.5%, with operating and profit margins of -1084.51% and -1038.04%.
| Gross Margin | -0.5% |
| Operating Margin | -1084.51% |
| Pretax Margin | -994.21% |
| Profit Margin | -1038.04% |
| EBITDA Margin | -6568.39% |
| EBIT Margin | -1084.51% |
| FCF Margin | -4168.26% |
Dividends & Yields
CBIO does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -49.53% |
| FCF Yield | -198.89% |
Analyst Forecast
Currently there are no analyst rating for CBIO.
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | n/a |
| Analyst Count | n/a |
Stock Splits
The last stock split was on Oct 31, 2023. It was a backward split with a ratio of 1:15.
| Last Split Date | Oct 31, 2023 |
| Split Type | backward |
| Split Ratio | 1:15 |
Scores
| Altman Z-Score | null |
| Piotroski F-Score | null |